We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+13.71%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$4.82B
AUM Growth
+$2.15B
Cap. Flow
+$1.73B
Cap. Flow %
35.86%
Top 10 Hldgs %
70.13%
Holding
71
New
9
Increased
19
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$82.8M
2
VYX icon
NCR Voyix
VYX
+$57.3M
3
LBTYA icon
Liberty Global Class A
LBTYA
+$48.3M
4
QDEL icon
QuidelOrtho
QDEL
+$46.2M
5
VTRS icon
Viatris
VTRS
+$41.3M

Top Sells

Rank Stock Value
1
CCJ icon
Cameco
CCJ
+$100M
2
HTZ icon
Hertz
HTZ
+$63.3M
3
NRG icon
NRG Energy
NRG
+$50.8M
4
HOLI
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
+$38.5M
5
FLR icon
Fluor
FLR
+$32.1M

Sector Composition

Rank Sector Weight
1 Healthcare 27.51%
2 Financials 5.41%
3 Technology 4.91%
4 Energy 4.01%
5 Materials 3.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PARR icon
26
Par Pacific Holdings
PARR
$3.79B
$43.6M 0.91%
1,199,749
-772,432
-39% -$26M
TAC icon
27
TransAlta
TAC
$3.94B
$42.8M 0.89%
5,145,630
+740,786
+17% +$5.98M
MATV icon
28
Mativ Holdings
MATV
$701M
$41.1M 0.85%
2,682,400
-1,317,600
-33% -$17.8M
GDRX icon
29
GoodRx Holdings
GDRX
$1.23B
$39.3M 0.82%
+5,872,806
New +$33.1M
PLYA
30
DELISTED
Playa Hotels & Resorts
PLYA
$38.3M 0.8%
4,431,161
-764,468
-15% -$5.76M
ZYME icon
31
Zymeworks
ZYME
$1.75B
$36.1M 0.75%
3,475,384
+823,990
+31% +$6.57M
LBTYK icon
32
Liberty Global Class C
LBTYK
$3.45B
$34.5M 0.72%
+1,852,856
New +$32.1M
MREO
33
Mereo BioPharma
MREO
$47.4M
$31.3M 0.65%
13,552,997
+1,936,877
+17% +$3.7M
XPER icon
34
Xperi
XPER
$320M
$28.2M 0.58%
2,555,632
-1,488,112
-37% -$14.3M
ARDX icon
35
Ardelyx
ARDX
$1.03B
$24.9M 0.52%
4,012,753
+1,512,753
+61% +$6.79M
SCPH
36
DELISTED
scPharmaceuticals
SCPH
$21.9M 0.46%
3,500,000
+786,713
+29% +$4.51M
ARQT icon
37
Arcutis Biotherapeutics
ARQT
$3.27B
$21.5M 0.45%
6,644,530
+1,610,000
+32% +$4.38M
RSKD icon
38
Riskified
RSKD
$792M
$19.5M 0.41%
4,173,636
+2,563,384
+159% +$10.5M
OABI icon
39
OmniAb
OABI
$500M
$17.6M 0.36%
2,850,588
– –
SILK
40
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$17.5M 0.36%
+1,427,905
New +$13.4M
OVID icon
41
Ovid Therapeutics
OVID
$491M
$17.1M 0.36%
5,315,969
-129,941
-2% -$444K
PCRX icon
42
Pacira BioSciences
PCRX
$967M
$16.6M 0.34%
491,322
+31,685
+7% +$927K
STRO icon
43
Sutro Biopharma
STRO
$328M
$14.3M 0.3%
334,481
– –
ADPT icon
44
Adaptive Biotechnologies
ADPT
$3.97B
$14M 0.29%
+2,862,729
New +$13.1M
RVNC
45
DELISTED
Revance Therapeutics, Inc.
RVNC
$12.8M 0.27%
1,461,474
-138,526
-9% -$1.13M
FIP icon
46
FTAI Infrastructure
FIP
$542M
$12.4M 0.26%
3,193,530
– –
TSAT icon
47
Telesat
TSAT
$916M
$10M 0.21%
959,764
– –
TRVI icon
48
Trevi Therapeutics
TRVI
$2.53B
$7.62M 0.16%
5,684,420
– –
HOWL icon
49
Werewolf Therapeutics
HOWL
$18.6M
$7.47M 0.16%
1,935,357
– –
CNNE icon
50
Cannae Holdings
CNNE
$642M
$7.08M 0.15%
+362,961
New +$6.61M
1
2
3

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
LAMI
Longview Asset Management (Illinois) Chicago, Illinois $9.56B AUM 25.94% 1-Year Est. Return

Rubric Capital Management (New York)'s Q4 2023 Portfolio in Review

As of Q4 2023, Rubric Capital Management (New York) held 71 positions worth $4.82B, up 81% from $2.67B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Rubric Capital Management (New York) deployed $1.73B of net new capital in Q4 2023, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was NCR Voyix: 3,591,228 shares worth $60.7M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 36% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Fluor, an estimated $32.1M trimmed.

  • Rubric Capital Management (New York)'s largest Q4 2023 buy was NCR Voyix: 3,591,228 shares worth $60.7M.
  • Rubric Capital Management (New York) added most to Roivant Sciences in Q4 2023, an estimated $82.8M increase.
  • Rubric Capital Management (New York)'s biggest Q4 2023 reduction was Fluor, cutting an estimated $32.1M.
  • Rubric Capital Management (New York) fully exited Cameco in Q4 2023, selling an estimated $100M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 70% of its $4.82B portfolio in Q4 2023.
  • Rubric Capital Management (New York) opened 9 new positions and closed 13 in Q4 2023.
  • Rubric Capital Management (New York)'s portfolio value rose 81% quarter-over-quarter to $4.82B.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2023, filed 13 Feb 2024.